Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome.
D015703:Antigens, CD / Q000235:genetics; D002648:Child; D016207:Cytokines / Q000097:blood; D003598:Cytoskeletal Proteins; D000068800:Etanercept; D010505:Familial Mediterranean Fever / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D007072:Immunoglobulin D; D007074:Immunoglobulin G / Q000008:administration & dosage*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D010507:Periodicity; D011506:Proteins / Q000235:genetics; D000071198:Pyrin; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage* / Q000235:genetics; D047888:Receptors, Tumor Necrosis Factor, Type I
D015703:Antigens, CD; D016207:Cytokines; D003598:Cytoskeletal Proteins; D007072:Immunoglobulin D; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; C000604192:MEFV protein, human; D011506:Proteins; D000071198:Pyrin; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D000068800:Etanercept